Empowered Patient Podcast

Karen Jagoda
  • 4.9 (16)
  • MEDICINA
  • CADA DÍA
Empowered Patient Podcast

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. HACE 14 H · CONTENIDO EXTRA

    Managing the Flood of Cancer Data to Support Oncologists with Dr. Tom Coughlin OncRef TRANSCRIPT

    Dr. Tom Coughlin, Founder and CEO of OncRef, has developed a platform that provides oncologists with a single source of information to keep up with the rapidly evolving field of cancer research and therapies. OncRef is addressing oncologists' information overload and time constraints, as well as curating and structuring the vast amount of available cancer data. The company recognizes the potential for AI and data-driven tools to advance cancer care while acknowledging the challenges of developing hallucination-proof AI models for use in the medical field.   Tom explains, "OncRef is looking to create a single source of truth for oncologists to keep up with the field of cancer. Cancer is now progressing so quickly with more personalized medicine. And now, with AI, more research publications are being published than ever, making it extremely hard to stay on top of this field. So, we're making it very easy by providing oncologists and oncology professionals with a single source of truth, all curated, and giving them exactly what they need rather than having them drink through the firehose of data out there because it's too much right now. So we're taking that pain out of it."  "The data is organized in a cancer-specific way. So, categorized by specific cancers and by having a consistent user interface and interaction, we just add the data to our interface so that the user can see what's changing over time. They do not have to wonder where the data is or be uncertain if they are getting lost in that information or perhaps missing what's happening on that constantly moving and progressing leading edge of cancer research." "We rely on a lot of government data and published information. This government data is sometimes very disorganized and unstructured. So, we have a robust team of data engineers that can structure the data and apply some categorization and labeling using our medical team, which curates the data so we can provide some structure to it to present it on our platform. That's really what we're most excited about. By structuring all of this unstructured data, we're setting the stage for a future Large Language Model or system that we can have less likelihood of hallucination. So, by having structured curated data, we will move towards something more reliable and give oncology an AI they can trust." #OncRef #CancerResearch #Cancer #Oncology #HeathTech #MedAI oncref.com Listen to the podcast here

  2. HACE 14 H

    Managing the Flood of Cancer Data to Support Oncologists with Dr. Tom Coughlin OncRef

    Dr. Tom Coughlin, Founder and CEO of OncRef, has developed a platform that provides oncologists with a single source of information to keep up with the rapidly evolving field of cancer research and therapies. OncRef is addressing oncologists' information overload and time constraints, as well as curating and structuring the vast amount of available cancer data. The company recognizes the potential for AI and data-driven tools to advance cancer care while acknowledging the challenges of developing hallucination-proof AI models for use in the medical field.   Tom explains, "OncRef is looking to create a single source of truth for oncologists to keep up with the field of cancer. Cancer is now progressing so quickly with more personalized medicine. And now, with AI, more research publications are being published than ever, making it extremely hard to stay on top of this field. So, we're making it very easy by providing oncologists and oncology professionals with a single source of truth, all curated, and giving them exactly what they need rather than having them drink through the firehose of data out there because it's too much right now. So we're taking that pain out of it."  "The data is organized in a cancer-specific way. So, categorized by specific cancers and by having a consistent user interface and interaction, we just add the data to our interface so that the user can see what's changing over time. They do not have to wonder where the data is or be uncertain if they are getting lost in that information or perhaps missing what's happening on that constantly moving and progressing leading edge of cancer research." "We rely on a lot of government data and published information. This government data is sometimes very disorganized and unstructured. So, we have a robust team of data engineers that can structure the data and apply some categorization and labeling using our medical team, which curates the data so we can provide some structure to it to present it on our platform. That's really what we're most excited about. By structuring all of this unstructured data, we're setting the stage for a future Large Language Model or system that we can have less likelihood of hallucination. So, by having structured curated data, we will move towards something more reliable and give oncology an AI they can trust." #OncRef #CancerResearch #Cancer #Oncology #HeathTech #MedAI oncref.com Download the transcript here

    20 min

  3. HACE 1 DÍA · CONTENIDO EXTRA

    Lab Data Insights Unlock Predictive Power to Improve Patient Care and Healthcare Efficiency with Bradley Bostic hc1 TRANSCRIPT

    Bradley Bostic, CEO of hc1, uses advanced data science, AI, and natural language processing to identify optimal patient testing, better predict disease development, and provide insights that can help prevent disease progression. The use of lab data is crucial for making diagnostic decisions, yet the potential of leveraging data is not being realized. Using technology to address issues like over-utilization of testing and data silos that prevent clinicians from seeing the complete story, hc1 is building a diagnostic insight network that unifies the provider and pharmacists to improve the patient journey and improve outcomes. Bradley explains, "We are transforming laboratories into strategic assets that improve patient care and boost the bottom line for healthcare systems. And really, the way that I came about this was having been in the healthcare industry for quite a while, most of my career, I started seeing this common fact that data was important. The largest component of the data that was used to make diagnostic decisions and diagnose patients was lab data. It's like 80% of all diagnostic decisions at least are informed by lab data. Yet, of everybody I saw out there looking to leverage data, there wasn't anybody that I saw who was hyper-specialized in how you can leverage signals from lab data to make patients healthier. I decided there was a void in the market and that we could be the best in the world. So that's what we've been working on here at hc1." "What we've been able to do is use these advanced data science capabilities, use artificial intelligence, use natural language understanding to not only be able to identify the optimal testing for patients at any given time to get to the best diagnosis faster. But also to become predictive - to identify those people in that constellation of signals who, for example, are trending toward developing chronic kidney disease or those people who are trending toward developing diabetes or any number of different disease states. We have created an artificial intelligence model that can identify individuals who are highly predisposed to developing cognitive decline well into the future without any sort of a specialized test, but just using routine test values all analyzed in this constellation."  #hc1 #HealthTechLeaders #LabData #HealthTech #HealthcareAI #HealthAI #FutureOfHealthcare #HealthcareTech #LabDiagnostics #HealthcareAnalytics hc1.com Listen to the podcast here

  4. HACE 1 DÍA

    Lab Data Insights Unlock Predictive Power to Improve Patient Care and Healthcare Efficiency with Bradley Bostic hc1

    Bradley Bostic, CEO of hc1, uses advanced data science, AI, and natural language processing to identify optimal patient testing, better predict disease development, and provide insights that can help prevent disease progression. The use of lab data is crucial for making diagnostic decisions, yet the potential of leveraging data is not being realized. Using technology to address issues like over-utilization of testing and data silos that prevent clinicians from seeing the complete story, hc1 is building a diagnostic insight network that unifies the provider and pharmacists to improve the patient journey and improve outcomes. Bradley explains, "We are transforming laboratories into strategic assets that improve patient care and boost the bottom line for healthcare systems. And really, the way that I came about this was having been in the healthcare industry for quite a while, most of my career, I started seeing this common fact that data was important. The largest component of the data that was used to make diagnostic decisions and diagnose patients was lab data. It's like 80% of all diagnostic decisions at least are informed by lab data. Yet, of everybody I saw out there looking to leverage data, there wasn't anybody that I saw who was hyper-specialized in how you can leverage signals from lab data to make patients healthier. I decided there was a void in the market and that we could be the best in the world. So that's what we've been working on here at hc1." "What we've been able to do is use these advanced data science capabilities, use artificial intelligence, use natural language understanding to not only be able to identify the optimal testing for patients at any given time to get to the best diagnosis faster. But also to become predictive - to identify those people in that constellation of signals who, for example, are trending toward developing chronic kidney disease or those people who are trending toward developing diabetes or any number of different disease states. We have created an artificial intelligence model that can identify individuals who are highly predisposed to developing cognitive decline well into the future without any sort of a specialized test, but just using routine test values all analyzed in this constellation."  #hc1 #HealthTechLeaders #LabData #HealthTech #HealthcareAI #HealthAI #FutureOfHealthcare #HealthcareTech #LabDiagnostics #HealthcareAnalytics hc1.com Download the transcript here

    24 min

  5. HACE 4 DÍAS · CONTENIDO EXTRA

    Pioneering Anti-Inflammatory Therapeutics with Dr. Niels Riedemann InflaRx TRANSCRIPT

    Niels Riedemann, the CEO, Founder, and Executive Director of the Board of InflaRx, explains that InflaRx develops pioneering anti-inflammatory therapeutics against a specific portion of the complement cascade, a part of the body’s immune system that responds to infectious microbes. By applying its proprietary monoclonal anti-C5a and anti-C5aR technologies, InflaRx hopes to affect the progression of a wide variety of inflammatory  diseases.  Niels explains, "Absolutely. So, I was a postdoc and research fellow at the University of Michigan and I researched this immune response I was talking about with another fellow in settings of sepsis of devastating, life-threatening inflammation and the other fellow and myself found it so intriguing that we ended up founding a company saying we're going to one day hopefully save people's lives with this approach by controlling this immune response. And when COVID came along, while we had a focus on other diseases and we have a key focus on devastating chronic diseases as well in the immune dermatological space and others, when COVID came along, we had all this knowledge and all this work in the immune response in life-threatening infections including in other viruses with our drug, for example, in an influenza type of virus. But we had not tested it, of course, in COVID or humans with this disease." "We felt we had to do something about it. We were very sure that this was a potential lifesaving approach. So we ended up running what we believe is the largest global study, a one-to-one randomized placebo-controlled study that was powered to show a benefit, a survival benefit, in the most severely sick COVID-patients. And when I say most severely sick, I really mean patients that need invasive mechanical ventilation or even lung replacement therapy, also called ECMO. So that's our focus, and we ended up showing a survival benefit. We may be talking about this a bit today, but it’s an interesting story and a life endeavor. I should probably also mention that in order to better understand the other side of the research part, I became a physician, and I actually ran a large academic ICU in Germany for almost seven years, and also enrolled patients in trials. So, I know how it is as an intensive care physician to take care of patients when they're that devastatingly sick. The lots of motivations within the company, and we are really glad that we could bring this drug forward to help patients." InflaRx.de Listen to the podcast here

  6. HACE 4 DÍAS

    Pioneering Anti-Inflammatory Therapeutics with Dr. Niels Riedemann InflaRx

    Niels Riedemann, the CEO, Founder, and Executive Director of the Board of InflaRx, explains that InflaRx develops pioneering anti-inflammatory therapeutics against a specific portion of the complement cascade, a part of the body’s immune system that responds to infectious microbes. By applying its proprietary monoclonal anti-C5a and anti-C5aR technologies, InflaRx hopes to affect the progression of a wide variety of inflammatory diseases.  Niels explains, "Absolutely. So, I was a postdoc and research fellow at the University of Michigan and I researched this immune response I was talking about with another fellow in settings of sepsis of devastating, life-threatening inflammation and the other fellow and myself found it so intriguing that we ended up founding a company saying we're going to one day hopefully save people's lives with this approach by controlling this immune response. And when COVID came along, while we had a focus on other diseases and we have a key focus on devastating chronic diseases as well in the immune dermatological space and others, when COVID came along, we had all this knowledge and all this work in the immune response in life-threatening infections including in other viruses with our drug, for example, in an influenza type of virus. But we had not tested it, of course, in COVID or humans with this disease." "We felt we had to do something about it. We were very sure that this was a potential lifesaving approach. So we ended up running what we believe is the largest global study, a one-to-one randomized placebo-controlled study that was powered to show a benefit, a survival benefit, in the most severely sick COVID-patients. And when I say most severely sick, I really mean patients that need invasive mechanical ventilation or even lung replacement therapy, also called ECMO. So that's our focus, and we ended up showing a survival benefit. We may be talking about this a bit today, but it’s an interesting story and a life endeavor. I should probably also mention that in order to better understand the other side of the research part, I became a physician, and I actually ran a large academic ICU in Germany for almost seven years, and also enrolled patients in trials. So, I know how it is as an intensive care physician to take care of patients when they're that devastatingly sick. The lots of motivations within the company, and we are really glad that we could bring this drug forward to help patients." InflaRx.de Download the transcript here

    18 min

  7. HACE 5 DÍAS · CONTENIDO EXTRA

    Tackling Emotional Barriers to Medication Adherence with Michael Oleksiw Pleio TRANSCRIPT

    Michael Oleksiw is the CEO of Pleio, a company focused on addressing the emotional barriers to patient engagement and medication adherence that medical professionals often overlook. Emotional barriers like loneliness, fear, and stigma can impact patients of all ages and backgrounds when they are facing a health challenge. Pleio uses technology and a peer-to-patient model to personalize interactions with empathetic humans, provide ongoing patient support, track emotional patterns, and bring pharmacists in to work with patients taking multiple medications or with chronic conditions.   Michael explains, "Our focus on the emotional barriers is meant to complement what’s out there today. The bulk of the focus when it comes to engaging patients and supporting patients is really on supporting the transaction, ensuring that a patient can get their medication, that they can get it cost-effectively, that they can pick it up, that it gets into their hands. But once they’re at home, everything gets real really fast and they’re faced with a variety of emotions such as loneliness, stigma, fear, etc. The American Medical Association recognizes that five of the eight major barriers to adherence are emotional, as I mentioned. So we try to stay in that swim lane and connect with the patient to target those barriers as a complement to all the stuff already being done out there." "You can say that we break White Coat syndrome in that we get the patient to focus on what’s important to them. Many times, patients don’t know or are intimidated by their healthcare professionals and don’t know how to engage in conversation. So one of the things we do is instill confidence so they can engage in fruitful conversations with their pharmacists and the like. So, the best way to think of it is we’re an extension of the pharmacy. We bring that trust and the care in the pharmacy into the home with what we call a peer-to-patient model where patients engage in conversation with people just like them to complement the baseline they received at the pharmacy." "Technology helps us be more efficient in terms of the patients we target, the words we choose, and the times we call. So, our view on technology is we use technology to support human interaction and make it better, optimize it, and make it more efficient, but not replace it. So, we don’t use technology to pretend to be human. Humans do a good job at that. I think humans could own being human. Technology is meant to support the human to be more efficient, make things more personalized, and take that step back to see the big picture and address trends over time." #Pleio #MedicationAdherence #PatientEngagement #EmotionalBarriers #MedAI #DigitalHealth pleio.com Listen to the podcast here

  8. HACE 5 DÍAS

    Tackling Emotional Barriers to Medication Adherence with Michael Oleksiw Pleio

    Michael Oleksiw is the CEO of Pleio, a company focused on addressing the emotional barriers to patient engagement and medication adherence that medical professionals often overlook. Emotional barriers like loneliness, fear, and stigma can impact patients of all ages and backgrounds when they are facing a health challenge. Pleio uses technology and a peer-to-patient model to personalize interactions with empathetic humans, provide ongoing patient support, track emotional patterns, and bring pharmacists in to work with patients taking multiple medications or with chronic conditions.   Michael explains, "Our focus on the emotional barriers is meant to complement what’s out there today. The bulk of the focus when it comes to engaging patients and supporting patients is really on supporting the transaction, ensuring that a patient can get their medication, that they can get it cost-effectively, that they can pick it up, that it gets into their hands. But once they’re at home, everything gets real really fast and they’re faced with a variety of emotions such as loneliness, stigma, fear, etc. The American Medical Association recognizes that five of the eight major barriers to adherence are emotional, as I mentioned. So we try to stay in that swim lane and connect with the patient to target those barriers as a complement to all the stuff already being done out there." "You can say that we break White Coat syndrome in that we get the patient to focus on what’s important to them. Many times, patients don’t know or are intimidated by their healthcare professionals and don’t know how to engage in conversation. So one of the things we do is instill confidence so they can engage in fruitful conversations with their pharmacists and the like. So, the best way to think of it is we’re an extension of the pharmacy. We bring that trust and the care in the pharmacy into the home with what we call a peer-to-patient model where patients engage in conversation with people just like them to complement the baseline they received at the pharmacy." "Technology helps us be more efficient in terms of the patients we target, the words we choose, and the times we call. So, our view on technology is we use technology to support human interaction and make it better, optimize it, and make it more efficient, but not replace it. So, we don’t use technology to pretend to be human. Humans do a good job at that. I think humans could own being human. Technology is meant to support the human to be more efficient, make things more personalized, and take that step back to see the big picture and address trends over time." #Pleio #MedicationAdherence #PatientEngagement #EmotionalBarriers #MedAI #DigitalHealth pleio.com Download the transcript here

    18 min
Ver todo (2 k)

4.9
de 5
16 calificaciones

Acerca de

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Información

  • Creador
    Karen Jagoda
  • Años de actividad
    2015 - 2025
  • Episodios
    2 k
  • Clasificación
    Apto
  • Copyright
    © 2024
  • Mostrar sitio web
    Empowered Patient Podcast

También te podría interesar

Para escuchar episodios explícitos, inicia sesión.

Mantente al día con este programa

Inicia sesión o regístrate para seguir programas, guardar episodios y enterarte de las últimas novedades.
Elige un país o región

Africa, Oriente Medio e India

Asia-Pacífico

Europa

Latinoamérica y el Caribe

Estados Unidos y Canadá